Oscar Health (OSCR) Price to Sales (2021 - 2026)

Oscar Health (OSCR) has reported Price to Sales for 6 consecutive years, with 1.6 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 4.25% year-over-year to 1.6; the trailing twelve-month figure through Jun 2026 stood at 0.51 (up 14.24% YoY), and the FY2025 full-year result was 0.32, up 2.14% from the prior year.
• Price to Sales advanced to 1.6 in Q2 2026 per OSCR's latest filing, from 0.65 in the prior quarter.
• Across five years, Price to Sales topped out at 1.85 in Q3 2024 and bottomed at 0.45 in Q4 2022.
• Historically, Price to Sales has averaged 1.18 across 5 years, with a median of 1.22 in 2023.
• The sharpest annual moves came in 2022 and 2023: Price to Sales slumped 91.23% in 2022, then soared 176.66% in 2023.
• Over 5 years, Price to Sales stood at 0.45 in 2022, then jumped by 176.66% to 1.24 in 2023, then decreased by 2.54% to 1.21 in 2024, then rose by 11.07% to 1.34 in 2025, then gained by 19.12% to 1.6 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 1.6, 0.65, and 1.34 for Q2 2026, Q1 2026, and Q4 2025 respectively.